Introduction
============

Lung cancer is the most lethal type of cancer in the United States and worldwide. In the United States, it is predicted that 222,500 new lung cancer patients will be diagnosed, and 155,870 people will die of lung cancer in 2018.[@b1-ott-11-4979] The death rate from lung cancer is 25%, the highest among all types of cancer. Smoking and being exposed to certain toxins are currently known direct reasons of lung cancer; however, many lung cancer cases occur without clear reasons. The recent discovery of several key driver gene mutations, including *EGFR*, *k-ras*, and *ALK*, opened a new era of understanding lung cancer and prompted the development of targeted therapies.[@b2-ott-11-4979] However, most lung cancers have no symptoms at initial stages and are advanced when diagnosed, resulting in poor prognosis. Many biomarkers critical for the diagnosis and treatment of lung cancer are emerging.

CEP55, also known as c10orf3 and FLJ10540, is encoded by the *CEP55* gene. It is widely expressed in different types of tissue, especially in proliferative tissues. It locates to the centrosomes at interphase and forms homodimers to assist cytokinesis.[@b3-ott-11-4979] Recently, CEP55 was found to be involved in the regulations of PI3K/AKT pathway and cancer cell stemness.[@b4-ott-11-4979]--[@b6-ott-11-4979] Clinically, CEP55 has been found overexpressed in multiple types of cancer, such as breast, prostate, renal, and thyroid cancers.[@b7-ott-11-4979]--[@b10-ott-11-4979] It has been included as a gene highly associated with prognosis in several patented mRNA microarrays used to screen for cancer diagnosis.[@b11-ott-11-4979],[@b12-ott-11-4979] However, the association of its protein level with prognosis of lung cancer patients has never been determined before. In this study, we used immunohistochemistry (IHC) and online datasets to determine the expression level of CEP55 in lung cancer patients and investigated its correlation with clinical parameters and prognosis.

Materials and methods
=====================

Patient selection
-----------------

This study was approved by the medical ethics committee of Sun Yat-Sen University Cancer Center. A total of 203 primary lung cancer specimens were obtained from primary surgery from October 2000 to April 2007. The selective criteria are as previously described.[@b13-ott-11-4979] To avoid confusion in data analysis, neoadjuvant chemotherapy patients were excluded. The histologic grade and clinical stage of the tumors were defined as previously described.[@b13-ott-11-4979] The final survival status of patients was confirmed in December 2013. Patients whose tissues and medical records were used for this study had provided written informed consent.

IHC staining
------------

IHC staining was performed to detect CEP55 expression according to the protocol previously described,[@b13-ott-11-4979] with minor changes. Tissue sections were deparaffinized with dimethylbenzene and then rehydrated through 100%, 95%, 90%, 80%, and 70% ethanol for 3 minutes each. After the PBS wash step, the slides were boiled for 15 minutes in citric acid in a microwave oven, followed by endogenous peroxidase blocking with 3% hydrogen peroxide. To retrieve antigen, the slides were then boiled in tris(hydroxymethyl) aminomethane-EDTA buffer (pH 8.0) in a microwave for 30 minutes. Nonspecific antigen binding was inhibited by incubation in 10% normal goat serum for 20 minutes. CEP55 antibody (1:1,000 dilution, Abgent, Rabbit Ig, San Diego, CA, USA) was incubated with slides overnight at 4°C in a moist chamber. For negative controls, slides were incubated with normal goat serum instead of the primary antibody. After the overnight incubation, the slides were sequentially incubated with biotinylated goat anti-rabbit antibody, streptavidin--peroxidase conjugate, and 3,3′-diaminobenzidine. Normal alveolar and bronchial epithelial mucosa were utilized as negative controls.

Immunoreactivity score (IRS) assessment
---------------------------------------

Two independent pathologists (Shanshan Lyu and Shumei Yan) who were blinded to the clinicopathological information performed the IRS assessment for CEP55 expression. The scoring criteria are as described previously.[@b13-ott-11-4979] The staining results were scored based on the 2 criteria: 1) the percentage of positive tumor cells in the tissue: 0 (0%), 1 (1%--10%), 2 (11%--50%), 3 (51%--75%), and 4 (76%--100%) and 2) the intensity of staining: 0, absent; 1, weak; 2, moderate and 3, strong. IRS was calculated by multiplying (1) and (2) (range from 0 to 12). The specimens were rescored if the difference between the two pathologists was \>3.

Statistical analysis
--------------------

The CEP55 IRS cutoff value was determined by the median of the staining results of 203 specimens. The correlation between CEP55 expression and clinicopathological features was analyzed by Pearson's *χ*^2^ test. Disease-free survival (DFS) was defined as the time from surgery to regional relapse or distant metastasis. Overall survival (OS) was defined as the time from surgery to death. DFS and OS curves in different subgroups were constructed by the Kaplan--Meier method. To test significant differences between 2 survival curves, we used HRs and their 95% CIs of covariates in the analyses of DFS or OS by Cox proportional hazards model. Multivariate analysis was performed for all of the parameters that were significant in the univariate analysis. Receiver operating characteristic (ROC) curve analysis was used to assess the predictive value of clinicopathologic features.

Data from previous publication were also utilized in this study.[@b13-ott-11-4979] Statistical analysis was performed using SPSS software (standard version 16.0, SPSS Inc., Chicago, IL, USA). A difference was considered statistically significance if the 2-sided probability value was less than 0.05.

Results
=======

Patient characteristics
-----------------------

Fifty-four females and 149 males, aged from 30 to 79 years (median 60.0 years), were included in this study. Among them, 122 were smokers and 81 were nonsmokers. The specific clinicopathological characteristics of the 203 patients are listed in [Table 1](#t1-ott-11-4979){ref-type="table"}.

Expression of CEP55 in non-small-cell lung carcinoma (NSCLC) and associations with clinicopathological characteristics
----------------------------------------------------------------------------------------------------------------------

In this study, the median CEP55 IRS value was \<8.0. IRS scores less than this value were considered low expression, and CEP55 IRS scores, greater than this value, were considered high expression. CEP55 staining of NSCLC tissue and normal alveolar and bronchial epithelial mucosa revealed that immunoreactivity primarily rests in the cytoplasm of tumor cells ([Figure 1](#f1-ott-11-4979){ref-type="fig"}). Low expression of CEP55 was observed in 37.4% (76/203) of the NSCLC samples, whereas 62.6% (127/203) of NSCLC samples had high expression of CEP55 ([Table 1](#t1-ott-11-4979){ref-type="table"}). The expression of CEP55 correlated closely with nodal status (*P*=0.004). No other statistical associations were observed between CEP55 expression and age, gender, smoking, tumor diameters, histology, histology grade, visceral pleural invasion, tumor status, TNM staging, and adjuvant chemotherapy (*P*=0.464, *P*=0.623, *P*=0.237, *P*=0.662, *P*=0.880, *P*=0.334, *P*=0.640, *P*=0.996, *P*=0.129, and *P*=0.110, respectively).

CEP55 expression and patient prognosis
--------------------------------------

All patients participated for the duration of this study. About 102 (50.24%) patients were deceased, and 101 patients were still alive at the end of the duration of this study. The 5-year OS rates of the whole cohort were 53.2% (108/203). OS and DFS curves for the whole cohort are shown in [Figure 2](#f2-ott-11-4979){ref-type="fig"}. Importantly, patients with high expression of CEP55 had a shorter OS and DFS compared with those with low expression (OS: mean of 73.04 versus 89.88 months, *P*=0.003; DFS: mean of 63.77 versus 84.73 months, *P*=0.005, [Figure 2](#f2-ott-11-4979){ref-type="fig"}, [Table 2](#t2-ott-11-4979){ref-type="table"}). CEP55 can differentiate between tumors in N or TNM staging and between those which have or have not been treated, with adjuvant chemotherapy ([Figure 2](#f2-ott-11-4979){ref-type="fig"}). High CEP55 expression was significantly associated with poor prognosis in NSCLC patients who are aged ≤60, females, nonsmokers, patients with tumor diameter \>3.5 cm, G2/3, and patients who had not received without adjuvant chemotherapy ([Figure 3](#f3-ott-11-4979){ref-type="fig"}, [Table 2](#t2-ott-11-4979){ref-type="table"}, DFS: *P*=0.006, *P*\<0.001, *P*=0.027, *P*=0.006, *P*=0.014, and *P*=0.022; OS: *P*=0.005, *P*\<0.001, *P*=0.018, *P*=0.004, *P*=0.008, and *P*=0.007).

Furthermore, univariate analysis using Cox's proportional hazard model showed that the following parameters correlated significantly with OS: tumor diameter, histological grade, tumor status, nodal status, TNM staging, AP3B expression, CEP55 expression, and adjuvant chemotherapy ([Table 3](#t3-ott-11-4979){ref-type="table"}). CEP55 and AP3B expression and clinicopathologic parameters that were significant in univariate analysis were further analyzed in multivariate analysis. The result demonstrated that nodal status, AP3B expression, and CEP55 expression were independent prognostic factors that affected NSCLC patients' OS ([Table 3](#t3-ott-11-4979){ref-type="table"}, *P*=0.050, *P*=0.003, *P*=0.036, respectively). High expression of CEP55 was a predictor for poor prognosis (HR, 1.617; 95% CI, 1.033--2.532; [Table 3](#t3-ott-11-4979){ref-type="table"}). High expression of AP3B was also a predictor for poor prognosis of NSCLC patients (HR, 1.893; 95% CI, 1.245--2.877; [Table 3](#t3-ott-11-4979){ref-type="table"}).

Combined increased expression of CEP55 and AP3B is correlated with poor prognosis in NSCLC
------------------------------------------------------------------------------------------

APOBEC3B, AP3B, is a newly defined DNA cytosine deaminase. Cytosine deamination resulting in cytosine to thymine (C-to-T) transition mutations, which is catalyzed by the APOBEC family, is a major source of DNA mutation in many different tumors. We retrieved data from 203 patients analyzed for a previous study[@b13-ott-11-4979] to analyze whether CEP55 and AP3B coexpression affects NSCLC prognosis. As shown in [Figure 4](#f4-ott-11-4979){ref-type="fig"}, when all NSCLC patients were stratified by AP3B expression, we found that the prognosis of patients with low CEP55 had significantly higher DFS and OS (*P*\<0.05, [Figure 4A and B](#f4-ott-11-4979){ref-type="fig"}). However, in patients with high AP3P expression, patients with low expression of CEP55 had significantly higher OS (*P*\<0.05, [Figure 4C](#f4-ott-11-4979){ref-type="fig"}), but showed no difference in DFS (*P*=0.065, [Figure 4D](#f4-ott-11-4979){ref-type="fig"}).

To determine whether coexpression of CEP55 and AP3B influence survival, patients were divided into 4 groups: 1 (CEP55−/AP3B−), 2 (CEP55+/AP3B−), 3 (CEP55−/AP3B+), and 4 (CEP55+/AP3B+). Group 1 patients had the best survival rate, and group 4 patients had the worst survival rate (mean OS: 99.82 vs 58.12 months; mean DFS: 97.41 vs 49.42 months). Group 2 and group 3 had moderate survivals rates.

ROC curves were plotted to evaluate the patients' survival status to assess prognostic values of CEP55, AP3B, or combined expression in NSCLC. ROC curve analysis showed promising predictive significance of CEP55 combined with AP3B expression in all NSCLC patients (area under the curve =0.665, *P*\<0.001, [Figure 4G](#f4-ott-11-4979){ref-type="fig"}). ROC curves of CEP55 and AP3B showed area under the curve of 0.600 and 0.616, which is also predictively significant (*P*=0.013 and *P*=0.004, respectively, [Figure 4G](#f4-ott-11-4979){ref-type="fig"}).

Discussion
==========

In this study, we showed that high expression of CEP55 is predictive of worse prognosis in lung cancer patients. Nodal status, AP3B expression, and CEP55 expression were independent prognostic factors that affected prognosis. Patients with low CEP55 and AP3B expression had the best survival rate, and patients with high CEP55 and AP3B expression had the worse survival rate. Previously, CEP55 had been shown to be a useful biomarker in breast, prostate, renal, and thyroid cancers.[@b7-ott-11-4979]--[@b10-ott-11-4979] However, its predictive value in lung cancer had not been reported.

CEP55 is a 55 kD centrosome- and midbody-associated protein. It contains 464 amino and was initially discovered as a key regulator of cytokinesis.[@b14-ott-11-4979],[@b15-ott-11-4979] Cytokinesis is a short and final step of the cell cycle during which the cytoplasmic division of a cell occurs and two daughter cells form. CEP55 localizes on the centrosome throughout the cell cycle and is recruited to the mitotic spindle and midbody during mitosis to recruit downstream machinery to it, which is critical for the correct assembly of the midbody. Consistently, CEP55 depletion in cells led to an increase in multinucleated cells and cells arrested at the midbody stage, which demonstrated the critical role of CEP55 in cytokinesis.[@b16-ott-11-4979],[@b17-ott-11-4979]

Apart from the cell cycle, CEP55 and the midbody are also associated with cell stemness. Stem cells and cancer cells accumulate more midbodies by evading autophagy, while differentiated cells possess high autophagic activity and do not accumulate midbodies.[@b6-ott-11-4979] Interestingly, our clinical analysis showed some similar results. We found that patients with higher histologic grade and TNM stages had a high ratio of positive CEP55 staining compared to those with well-differentiated tumors and lower TNM stages. Additionally, patients with lymph node metastasis demonstrated a higher ratio of positive CEP55 staining than those without lymph node metastasis. These clinical observations suggest that high expression of CEP55 correlates with cancer cell stemness, which is consistent with previous studies.

Another possible explanation of the high ratio of CEP55 expression in more advanced stage lung cancer patients is due to its activation of PI3K/AKT pathway, a major prosurvival pathway in cancer cells. CEP55 has been reported to bind to PIK3CA and stabilize it, leading to increased S473 phosphorylation of AKT in lung cancer.[@b18-ott-11-4979] In addition, the CEP55/PI3K/AKT pathway leads to increased migration and invasion of lung cancer cells.[@b19-ott-11-4979] Thus, the activation of AKT could be a critical oncogenic factor of these advanced stage lung cancer patients.

We conclude that CEP55 is an independent prognostic factor in lung cancers. In the Kaplan--Meier plots, lung cancer patients with high CEP55 expression have shorter survival time than those with low CEP55 expression. We also extracted Kaplan--Meier plots from SurveExpress online database and found similar results, further supporting our conclusions. As mentioned before, overexpression of CEP55 has been reported to predict poor prognosis in ovarian carcinoma, esophageal squamous cell carcinoma, bladder, breast, and thyroid cancers. Of note, in the last few decades, CEP55 has been identified as being overexpressed in mRNA microarray expression profiles of many human cancers, including gastric, hepatocellular, lung, and bladder carcinoma.[@b4-ott-11-4979],[@b18-ott-11-4979],[@b20-ott-11-4979],[@b21-ott-11-4979] CEP55 was included in the top 70 most highly overexpressed genes in CIN 70 and in a signature in patented prognostic kits for the prediction of malignancy risk, prognosis, and therapy resistance in multiple human cancers.[@b22-ott-11-4979] CEP55 was also part of commercial signatures from Myriad Genetics Inc. and PAM50 for diagnosis and prognostic prediction of lung and other types of cancers.[@b23-ott-11-4979]

More importantly, it has been reported that CEP55 can act as a cancer vaccine target. It is not only a tumor-associated antigen but also aberrantly expressed in tumors, making it ideal for immunotherapy vaccines.[@b24-ott-11-4979] Previous studies have shown that CEP55 peptides were able expand and activate cytotoxic T lymphocyte clonally in vitro and in vivo.[@b25-ott-11-4979],[@b26-ott-11-4979] Exciting results have been shown in the treatment of chemotherapy-resistant colon cancer cells.

Our results fill in the blank in the prognostic prediction of lung cancer patients by IHC, which strengthened the clinical significance of CEP55. All these findings demonstrate that both CEP55 RNA and protein levels can act as prognostic factors in multiple cancers and might be a good treatment target in cancer immunotherapies.

Another intriguing investigation direction is about the regulation of CEP55 by driver genes in cancers. Although it has been demonstrated that FOXM1 transactivates CEP55 and PLK1 stabilizes it, few papers cover the relationship of CEP55 with key driver mutations in lung cancer, such as ALK, EGFR, k-ras, and met.[@b12-ott-11-4979],[@b27-ott-11-4979] As an important oncogenic factor, the activity of CEP55 must be strictly regulated in cells. Thus, it deserves more studies both clinically and mechanistically. We admit that this study has limitations. It was conducted only in one institution; further verifications from other independent investigators are needed. Additionally, key mutation information was not included in our data, so correlational analyses between CEP55 and other known mutations could not be performed.

Overall, our local and online analyses led to the conclusion that lung cancer patients with high CEP55 expression have shorter OS and DFS compared with those with low CEP55 expression. CEP55 might be associated with stemness of lung cancer cells, and it can be an independent predictor of survival for patients with lung cancer. Further studies are warranted.
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![CEP55 expression is determined by IHC.\
**Notes:** No or low expression of CEP55 protein in the cytoplasm of adjacent normal tissue (magnification: **A**, 200×; **B**, 400×). (**C,D**) Low expression level of CEP55 in epithelial NSCLC tissues (magnification: **C**, 200×; **D**, 400×). (**E**, **F**) High expression levels of CEP55 in epithelial NSCLC tissues (magnification: **E**, 200×; **F**, 400×). (**G**, **H**) Low expression level of CEP55 in adeno-NSCLC tissues (magnification: **G**, 200×; **H**, 400×). (**I**, **J**) High expression levels of CEP55 in adeno-NSCLC tissues (magnification: **I**, 200×; **J**, 400×).\
**Abbreviations:** IHC, immunohistochemistry; NSCLC, non-small-cell lung cancer.](ott-11-4979Fig1){#f1-ott-11-4979}

![OS curve and DFS curve of 203 NSCLC patients based on different clinicopathological characteristics and CEP55 expression.\
**Notes:** (**A**, **B**) OS curve and DFS curve in NSCLC patients with high and low levels of CEP55 expression. (**C**, **D**) OS curve and DFS curve in NSCLC patients with N=0 or N\>0. (**E**, **F**) OS curve and DFS curve in NSCLC patients with different TNM staging. (**G**, **H**) OS curve and DFS curve in NSCLC patients with or without chemotherapy.\
**Abbreviations:** DFS, disease-free survival; NSCLC, non-small-cell lung cancer; OS, overall survival.](ott-11-4979Fig2){#f2-ott-11-4979}

###### 

Subgroup analysis of patients with NSCLC based on their CEP55 expression.

**Notes:** (**A**, **B**) OS curve and DFS curve: patients aged ≤60 with high and low levels of CEP55 expression. (**C, D**) OS curve and DFS curve: female patients with high and low levels of CEP55 expression. (**E**, **F**) OS curve and DFS curve: nonsmoker patients with high and low levels of CEP55 expression. (**G**, **H**) OS curve and DFS curve: patients with tumor diameters \>3.5 cm with high and low levels of CEP55 expression. (**I**, **J**) OS curve and DFS curve: patients with histological grade 2 or 3 and high and low levels of CEP55 expression. (**K**, **L**) OS curve and DFS curve: patients who underwent no chemotherapy with high and low levels of CEP55 expression.

**Abbreviations:** DFS, disease-free survival; NSCSC, non-small-cell lung cancer; OS, overall survival.
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###### 

OS and DFS curves of patients with NSCLC based on their AP3B and CEP55 expression.

**Notes:** (**A**, **B**) OS curve and DFS curve: patients who have low AP3B expression levels with high and low levels of CEP55 expression. (**C**, **D**) OS curve and DFS curve: patients who have high AP3B expression levels with high and low levels of CEP55 expression. (**E**, **F**) OS curve and DFS curve of 4 groups of patients according to AP3B and CEP55 expression: CEP55−/AP3B−, CEP55+/AP3B−, CEP55−/AP3B+, and CEP55+/AP3B+. (**G**) ROC curve of CEP55 only, AP3B only, and CEP55 combined with AP3B.

**Abbreviations:** DFS, disease-free survival; NSCSC, non-small-cell lung cancer; OS, overall survival; ROC, receiver operating characteristic.
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###### 

Correlation between CEP55 expression and clinicopathological variables of lung cancer cases

  Variables                   Cases (n=203)   CEP55 expression   *P*-value   
  --------------------------- --------------- ------------------ ----------- -----------
  Age (years)                                                                0.464
   ≤60                        101             37                 64          
   \>60                       102             39                 63          
  Gender                                                                     0.623
   Male                       149             54                 95          
   Female                     54              22                 32          
  Smoking                                                                    0.237
   No                         81              26                 55          
   Yes                        122             50                 72          
  Tumor diameter                                                             0.662
   \<3.5 cm                   91              36                 55          
   ≥3.5 cm                    112             40                 72          
  Histology                                                                  0.880
   SCC                        71              26                 45          
   Non-SCC                    132             50                 82          
  Histological grade                                                         0.334
   I                          28              14                 14          
   II                         84              30                 54          
   III                        91              32                 59          
  Visceral pleural invasion                                                  0.640
   Absent                     64              22                 42          
   Present                    139             54                 85          
  Tumor status (T)                                                           0.996
   T1                         39              14                 25          
   T2                         138             52                 86          
   T3                         18              7                  11          
   T4                         8               3                  5           
  Nodal status (N)                                                           **0.004**
   N0                         115             54                 61          
   N1                         37              7                  30          
   N2                         51              15                 36          
  TNM staging                                                                0.129
   I                          90              40                 50          
   II                         56              20                 36          
   III                        57              16                 41          
  Adjuvant chemotherapy                                                      0.110
   No                         110             47                 63          
   Yes                        93              29                 64          

**Note:** Statistically significant *P* value is shown in bold.

**Abbreviation:** SCC, squamous cell carcinoma.

###### 

CEP55 expression in lung cancer patients by Kaplan--Meier 5-year survival analysis (log-rank test)

  Variables               Case   DFS (months)   OS (months)                                    
  ----------------------- ------ -------------- ------------- ------------- --------- -------- -------------
  Total                                                                                        
   Low expression         76     84.73          NR            **0.005**     89.876    NR       **0.003**
   High expression        127    63.736         39.970                      73.040    66.100   
  Age categories                                                                               
   ≤60                                                        **0.006**                        **0.005**
    Low expression        37     89.181         NR                          94.079    NR       
    High expression       64     56.286         24.670                      65.503    55.430   
   \>60                                                       0.276                            0.203
    Low expression        39     80.168         NR                          85.459    NR       
    High expression       63     69.473         59.870                      75.327    71.330   
  Gender categories                                                                            
   Male                                                       0.281                            0.253
    Low expression        54     76.011         NR                          82.397    NR       
    High expression       95     66.121         51.600                      74.113    70.030   
   Female                                                     \<**0.001**                      \<**0.001**
    Low expression        22     104.230        NR                          106.665   NR       
    High expression       32     55.996         27.870                      61.395    42.970   
  Smoking categories                                                                           
   Yes                                                        0.064                            0.059
    Low expression        50     80.846         NR                          86.482    NR       
    High expression       72     62.201         38.270                      70.829    69.600   
   No                                                         **0.027**                        **0.018**
    Low expression        26     91.148                                     95.294             
    High expression       55     64.230         43.070                      70.925    56.170   
  Tumor diameters                                                                              
   ≤3.5 cm                                                    0.270                            0.265
    Low expression        36     85.021         NR                          90.339    NR       
    High expression       55     75.385         66.100                      84.851    99.770   
   \>3.5 cm                                                   **0.006**                        **0.004**
    Low expression        40     83.342         NR                          88.281    NR       
    High expression       72     54.457         22.870                      60.395    35.900   
  Histologic grade                                                                             
   G1                                                         0.386                            0.405
    Low expression        14     94.726         NR                          95.631    NR       
    High expression       14     84.551         101.530                     88.402    NR       
   G2/3                                                       **0.014**                        **0.008**
    Low expression        62     82.081         NR                          88.297    NR       
    High expression       113    60.662         37.930                      68.750    56.170   
  N categories                                                                                 
   N=0                                                        0.216                            0.197
    Low expression        54     95.888         NR                          98.706    NR       
    High expression       61     88.314         NR                          93.458    NR       
   N=1/2                                                      0.137                            0.106
    Low expression        22     55.003         35.870                      66.833    45.070   
    High expression       66     40.343         17.300                      49.892    29.800   
  Adjuvant chemotherapy                                                                        
   Yes                                                        0.183                            0.210
    Low expression        47     84.579         NR                          87.670    NR       
    High expression       63     74.523         71.330                      79.894    91.370   
   No                                                         **0.022**                        **0.007**
    Low expression        29     84.761         NR                          93.100    NR       
    High expression       64     52.872         19.930                      62.255    50.830   

**Note:** Statistically significant *P* values are shown in bold.

**Abbreviations:** DFS, disease-free survival; NR, not reached; OS, overall survival.

###### 

Univariate and multivariate analyses of OS of lung cancer patients

  Variables                           Univariate analyses   Multivariate analyses                                        
  ----------------------------------- --------------------- ----------------------- ------------- ------- -------------- -----------
  Age (years) (≤58 vs \>58)           1.022                 0.693--1.507            0.912                                
  Gender (male vs female)             1.074                 0.692--1.668            0.750                                
  Smoking (yes vs no)                 1.038                 0.698--1.542            0.855                                
  Tumor diameter (≤3.5 vs \>3.5 cm)   1.508                 1.015--2.424            **0.042**     1.048   0.658--1.669   0.843
  Histological grade (III/II/I)       1.353                 1.012--1.808            **0.041**     1.216   0.862--1.715   0.265
  Tumor status (T4/T3/T2/T1)          1.496                 1.121--1.997            **0.006**     1.116   0.758--1.645   0.577
  Nodal status (N\>0/N0)              3.398                 2.260--5.109            \<**0.001**   2.210   0.958--4.957   **0.050**
  TNM staging (III/II/I)              1.889                 1.502--2.376            \<**0.001**   1.230   0.756--1.999   0.405
  AP3B expression (high/low)          2.066                 1.383--3.806            \<**0.001**   1.893   1.245--2.877   **0.003**
  CEP55 expression (high/low)         1.895                 1.226--2.920            **0.004**     1.617   1.033--2.532   **0.036**
  Adjuvant chemotherapy (yes vs no)   0.639                 0.433--0.942            **0.024**     1.080   0.711--1.640   0.719

**Note:** Statistically significant *P* values are shown in bold.

**Abbreviation:** OS, overall survival.
